PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $19.63 million. The enterprise value is $26.16 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 31.16 million shares outstanding. The number of shares has increased by 879.09% in one year.
Current Share Class | 31.16M |
Shares Outstanding | 31.16M |
Shares Change (YoY) | +879.09% |
Shares Change (QoQ) | -60.22% |
Owned by Insiders (%) | 4.31% |
Owned by Institutions (%) | 7.82% |
Float | 27.25M |
Valuation Ratios
The trailing PE ratio is 0.66.
PE Ratio | 0.66 |
Forward PE | n/a |
PS Ratio | 3.47 |
Forward PS | 65.22 |
PB Ratio | 0.56 |
P/TBV Ratio | 1.05 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | 0.36 |
EV / Sales | 13.13 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37, with a Debt / Equity ratio of 0.23.
Current Ratio | 0.37 |
Quick Ratio | 0.28 |
Debt / Equity | 0.23 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,087.79 |
Financial Efficiency
Return on equity (ROE) is 644.12% and return on invested capital (ROIC) is -56.60%.
Return on Equity (ROE) | 644.12% |
Return on Assets (ROA) | -49.81% |
Return on Invested Capital (ROIC) | -56.60% |
Return on Capital Employed (ROCE) | -83.40% |
Revenue Per Employee | $51,103 |
Profits Per Employee | $1.86M |
Employee Count | 39 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.82% in the last 52 weeks. The beta is 1.12, so PAVmed's price volatility has been higher than the market average.
Beta (5Y) | 1.12 |
52-Week Price Change | -64.82% |
50-Day Moving Average | 0.71 |
200-Day Moving Average | 0.87 |
Relative Strength Index (RSI) | 40.60 |
Average Volume (20 Days) | 174,938 |
Short Selling Information
The latest short interest is 233,297, so 0.75% of the outstanding shares have been sold short.
Short Interest | 233,297 |
Short Previous Month | 237,355 |
Short % of Shares Out | 0.75% |
Short % of Float | 0.86% |
Short Ratio (days to cover) | 1.97 |
Income Statement
In the last 12 months, PAVmed had revenue of $1.99 million and earned $72.45 million in profits. Earnings per share was $0.96.
Revenue | 1.99M |
Gross Profit | -1.14M |
Operating Income | -35.90M |
Pretax Income | -61.46M |
Net Income | 72.45M |
EBITDA | -35.24M |
EBIT | -35.90M |
Earnings Per Share (EPS) | $0.96 |
Full Income Statement Balance Sheet
The company has $2.70 million in cash and $9.24 million in debt, giving a net cash position of -$6.54 million or -$0.21 per share.
Cash & Cash Equivalents | 2.70M |
Total Debt | 9.24M |
Net Cash | -6.54M |
Net Cash Per Share | -$0.21 |
Equity (Book Value) | 40.93M |
Book Value Per Share | 1.12 |
Working Capital | -6.14M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$22.03 million and capital expenditures -$19,000, giving a free cash flow of -$22.05 million.
Operating Cash Flow | -22.03M |
Capital Expenditures | -19,000 |
Free Cash Flow | -22.05M |
FCF Per Share | -$0.71 |
Full Cash Flow Statement Margins
Gross margin is -57.15%, with operating and profit margins of -1,801.15% and 3,711.54%.
Gross Margin | -57.15% |
Operating Margin | -1,801.15% |
Pretax Margin | 3,289.61% |
Profit Margin | 3,711.54% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -879.09% |
Shareholder Yield | -879.09% |
Earnings Yield | 369.15% |
FCF Yield | -112.33% |
Dividend Details Analyst Forecast
The average price target for PAVmed is $19.50, which is 2,996.22% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $19.50 |
Price Target Difference | 2,996.22% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | 153.17% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on December 7, 2023. It was a reverse split with a ratio of 0.0666667:1.
Last Split Date | Dec 7, 2023 |
Split Type | Reverse |
Split Ratio | 0.0666667:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |